Ameriprise’s PDL BioPharma, Inc. PDLI Stock Holding History

Ameriprise’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-322,473	Closed	-$948K	–	3775
2018 Q1	$948K	Sell	322,473 -57,449	-15%	-$157K	﹤0.01%	2991
2017 Q4	$1.04M	Buy	379,922 +365,973	+2,624%	+$1.12M	﹤0.01%	2959
2017 Q3	$47K	Buy	+13,949	New	+$38.8K	﹤0.01%	3637
2015 Q1	–	Sell	-12,252	Closed	-$95K	–	4035
2014 Q4	$95K	Sell	12,252 -3,619	-23%	-$28.6K	﹤0.01%	3594
2014 Q3	$119K	Sell	15,871 -33	-0.2%	-$306	﹤0.01%	3607
2014 Q2	$154K	Buy	15,904 +9,373	+144%	+$83.5K	﹤0.01%	3422
2014 Q1	$54K	Buy	6,531 +2,271	+53%	+$19.5K	﹤0.01%	3767
2013 Q4	$36K	Sell	4,260 -8,305	-66%	-$70K	﹤0.01%	3799
2013 Q3	$100K	Sell	12,565 -166	-1%	-$1.33K	﹤0.01%	3466
2013 Q2	$98K	Buy	+12,731	New	+$99.3K	﹤0.01%	3401

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Ameriprise's PDLI Position: Q2 2018 in Review

Ameriprise sold out of PDL BioPharma, Inc. (PDLI) in Q2 2018, closing a stake of 322,473 shares — an estimated $948K sold.

Ameriprise first reported a position in PDLI in Q2 2013 and held it in 10 quarters. The position peaked at $1.04M in Q4 2017. 163 funds tracked by Wall St. Rank hold PDLI as of Q2 2018.

Ameriprise reported no remaining PDL BioPharma, Inc. position as of Q2 2018 after selling out during the quarter.
Ameriprise sold 322,473 PDL BioPharma, Inc. shares in Q2 2018, an estimated $948K.
Ameriprise first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 10 quarters.
Ameriprise's PDL BioPharma, Inc. position peaked at $1.04M in Q4 2017.
163 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2018.

Based on Ameriprise's 13F filing for Q2 2018, filed 14 Aug 2018.